Evidence map›Paper›PMID 40595023›Full record

ArticleScientific reports2025

RDM1 plays an oncogenic role in clear cell renal cell carcinoma potentially by modulating MCM2.

Xiuming Li, Hui Liu, Yujie Wei, Anxin Wang, Chengcheng Lv, Yu Zeng

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiuming Li *Hebei Key Laboratory of Panvascular Diseases, Chengde, 067000, Hebei, China.
Hui Liu *Department of Pharmacology, College of Traditional Chinese Medicine, Chengde Medical University, Chengde, 067000, Hebei, China.
Yujie WeiDepartment of Urology, Affiliated Hospital of Chengde Medical University, Chengde, 067000, Hebei, China.
Anxin WangDepartment of Pharmacology, College of Traditional Chinese Medicine, Chengde Medical University, Chengde, 067000, Hebei, China.
Chengcheng LvDepartment of Urology, the Cancer Hospital of China Medical University & Liaoning Cancer Hospital and Institute, Shenyang, 110042, Liaoning, China.
Yu ZengDepartment of Urology, the Cancer Hospital of China Medical University & Liaoning Cancer Hospital and Institute, Shenyang, 110042, Liaoning, China. zengyud07@foxmail.com.

Funding

Natural Science Foundation of Hebei Province H2021406054Natural Science Foundation of Hebei Province H2023406033Science and Technology Research Program of the Hebei Provincial Department of Education QN2022114
6 · The paper itself

Abstract

Kidney cancer may result from different gene mutations, each contributing to different histological subtypes and prognoses. RAD52 motif-containing 1 (RDM1) regulates multiple cancer pathways, but its role in ccRCC is unknown to date. According to our results, RDM1 expression increased in ccRCC cells, which was correlated to poor survival in ccRCC patients. Knockdown of RDM1 arrested the cell cycle, promoted cell apoptosis, and apparently suppressed ccRCC cell growth in vitro and in vivo. From the mechanism perspective, RDM1 drove MCM2 to modulate ccRCC cell cycle. Thus, RDM1 inhibition blocks cell cycle progression, suppresses ccRCC cell growth, and is a promising approach for treating ccRCC.

Indexed as

Carcinoma, Renal CellDNA Repair EnzymesKidney NeoplasmsMinichromosome Maintenance Complex Component 2AnimalsApoptosisCell CycleCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceDNA Repair EnzymesMCM2 protein, humanMinichromosome Maintenance Complex Component 2

Identifiers

PMID40595023
PMCPMC12214518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.